Company ProfilePremium

Daebongls.Co., Ltd.

Company Profile Analysis

Ticker: 078140.KQ대봉엘에스 주식회사

ESOMAR 23 Corporate BadgeISO Certifications Badge
Daebongls.Co., Ltd. - Company showcase

Year Founded & Workforce

1986

144 Employees

Daebongls.Co., Ltd. logo

Daebongls.Co., Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Daebongls.Co., Ltd. Overview

Daebong LS is a small-cap Korean specialty-materials company. It now calls itself a "cosmetics, pharmaceutical and bio materials platform". The core business is selling and making active and functional cosmetic ingredients. These are its own Jeju- and fermentation-derived actives plus a distribution portfolio from global majors BASF and Lubrizol (including Lipotec peptides). The company says it serves more than 800 OEM/ODM and brand customers.

A second leg is a GMP/PIC/S-certified active pharmaceutical ingredient (API) business focused on respiratory, hypertension and digestive therapies. This business is now moving into incrementally modified drugs (IMDs) and peptide APIs, including a liraglutide CDMO alliance with India's Shilpa Pharma Lifesciences.

The third leg is the 54–59%-owned P&K Skin Research Center, which runs human-application efficacy testing for cosmetics and gives the group a "material plus clinical data" offering. FY2025 revenue first passed KRW 100B. However, operating margins and free cash flow have weakened after the debt-funded move to the Songdo B&H Plex campus.


What the company does

Daebong LS sources, manufactures, formulates and sells raw materials. Its customers are cosmetics makers, pharmaceutical makers and (historically) food and feed producers. Third-party descriptions (Investing.com/S&P Global, MarketScreener) identify three operating divisions:

  1. Cosmetic Ingredients.

    • Proprietary specialty actives, many based on Jeju Island botanicals: fresh green tea, black ginseng water, Jeju gulfweed, Artemisia capillaris, Jeju camellia oil, daengyuji citrus, basalt volcanic ash, ginseng flower.

    • Natural and synthetic functional ingredients for moisturising, protection, whitening, anti-ageing, hair care, anti-pollution, conditioning and colour.

    • Distributed commodity and specialty materials: aloe vera gel, beta-carotene, calamine, Diaformer, Emulgade, emulsifiers, emollients, polymers and thickeners.

  2. Pharmaceutical Raw Materials.

    • Development and production of APIs for respiratory, hypertension, digestive and hyperlipidaemia therapies.

    • Named materials include almagate, bentonite, calcitriol, erdosteine and fish oil.

    • Excipient supply to Korean drug makers as an agent for global companies.

  3. Food & Feed. Functional additives, proteins, amino acids, vitamins and fish feed. Compound fish feed is supplied to the affiliate Daebong LF Fishery Association, and the company owns a Bio-secure Aquaculture System (BAS) technology.

The consolidated group adds a clinical/efficacy-testing business through the listed subsidiary P&K Skin Research Center. P&K covers cosmetics, health functional foods, beauty devices and in-vitro testing.

Current revenue mix (H1 2026)

KIRS (8 Oct 2026) reports the H1 2026 sales mix as:

cosmetic materials 63%: - pharmaceutical materials 15%

other / subsidiaries 22%: (mainly P&K)

Under DART's reported segments, Butler shows the Q2 2026 mix as manufacturing 79%, research (P&K) 20% and rental 1%.

Business and revenue model

DimensionCharacterisation
Product vs serviceMainly product sales (ingredients and APIs, about 78–80% of revenue). Fee-for-service testing (P&K, about 20–22%). Small rental income after the Songdo campus completion (about 1%)
Own vs distributedMixed. The company manufactures its own actives and APIs at Incheon and acts as a distributor for BASF and Lubrizol (Lipotec) cosmetic materials and for global excipient makers. KIRS cites a portfolio of 1,200+ cosmetic materials. StockHub cites about 400 eco-natural and bio-synthetic derma materials, probably the proprietary or manufactured subset
LicensingEmerging. The company targets technology transfers (out-licensing) of IMD candidates (L-erdosteine, epinaconazole co-crystal) by end-2026. No licensing revenue has been disclosed to date
Subscription—
Customer typesCosmetic OEM/ODM manufacturers, brand owners (including indie K-beauty brands), domestic pharmaceutical companies, overseas distributors/agents (20+ countries), and feed users
End-marketsSkincare and derma-cosmetics, hair care, post-procedure/aesthetic care, generic and IMD pharmaceuticals (respiratory, cardiovascular, GI), medical devices (Class II wound dressing), food/feed

Value-chain position

Daebong LS sits upstream of K-beauty brand owners and contract manufacturers (Cosmax, Kolmar Korea and others) and of domestic pharmaceutical formulators. It combines three roles:

Ingredient innovator: own actives with Korean and international patents and publications.

Specialty distributor/formulation consultant: BASF/Lubrizol materials plus guide formulations.

Data provider: P&K efficacy claims substantiation.

The company's stated aim is a "one-stop" chain from material to formulation to clinical substantiation. The 2025 Songdo B&H Plex co-locates Daebong LS, the OEM/ODM affiliate UCL and P&K to deliver this (MT, 19 Dec 2025).

Company self-description vs independent view

Company self-description (2025–26 press releases): a "cosmetics, pharmaceutical and bio materials platform company". Its mission is to provide the best solutions so people can live healthier and more beautiful lives (SCC/UL Prospector company text, paraphrased). It emphasises a multi-brand, multi-category structure not dependent on any single brand or product line (CosinKorea, 18 Aug 2026).

Independent characterisation: a family-controlled small-cap. Its economic engine is cosmetic-ingredient trading and manufacturing with modest margins: FY2025 gross margin 27.9%, operating margin 7.2%. Historically the standalone parent earned very thin operating margins (1.5% in FY2020). Consolidated profitability has depended on the higher-margin P&K subsidiary and on non-operating financial income from a large portfolio of financial assets. The pharma IMD and peptide pipeline is option value, not yet a revenue line.

Strategy

Stated strategic themes (paraphrased from 2025–26 company communications)

  1. "Cosmetics, pharmaceutical and bio materials platform." Integrate material development, formulation, manufacturing and clinical substantiation in one location (Songdo B&H Plex).

  2. High-value bio materials. Shift the mix toward peptides, PDRN, exosomes, ceramides and DDS-encapsulated actives. In H2 2026 the company plans to raise the sales share of peptides and PDRN (CosinKorea, 18 Aug 2026).

  3. "Medical beauty" as a new growth engine. Medical devices (DB JINO line) and derma products sold through hospitals, pharmacies and Olive Young; described as entering a sales-expansion phase in Q1 2026 (Financial News, 18 May 2026).

  4. From API maker to IMD developer. Out-license L-erdosteine and the epinaconazole co-crystal (target end-2026). Commercialise vonoprazan and azilsartan IMDs and generic APIs. Peptide APIs (liraglutide via Shilpa). Management described the Nov 2025 conference as an "inflection point" (Finance Scope, 26 Nov 2025).

  5. Globalisation of the ingredient business. Distributor agreements in about 20 countries (2024); partnership with Azelis Indonesia for ASEAN; trade shows in Korea, Asia, Japan and Europe.

  6. Multi-brand, multi-category resilience. Avoid concentration on any single brand or product (CosinKorea, 18 Aug 2026).

  7. Open innovation and national R&D. KEIT lutein project; participation in the Kookmin University-led KRW 22.2B advanced bio-materials programme; KHIDI global-GMP support.

Initiatives announced in the last 24 months

DateInitiativeDetailSource
Sep 2024 – Nov 2025Shilpa GLP-1 allianceNDA (Sep 2024) → MOU (Dec 2024) → production-schedule talks (Mar 2025) → Shilpa CTO presents a Korea and Thailand GLP-1 commercialisation roadmap at Daebong's conference (Nov 2025)Dailypharm; Finance Scope
2024–2025Songdo B&H PlexGroup HQ, R&D and clinical campus; construction contract about KRW 56.4BDealsite; MT
2,025New cosmetic activesL-PDRN First, RedCabbage ExoSkin, DecelAge Peptide, Tremella Dual-OligoCosinKorea
Jan 2026Medical device entryDB JINO Algi Bio Cell MD (Class II)Cosmorning
2,026KHIDI global GMP supportUpgrade GMP and quality systems for pharmaceutical amino acids; build FDA regulatory capability for US/EU entryFinancial News, 7 Jul 2026
Jul 2026KEIT lutein projectLead organisation; KRW 5B total budget; Jun 2026–Dec 2030 (about 56 months); partners GS Caltex, Silicobio (KAIST-derived strain technology), Dankook UniversityFinancial News; Geconomy, Jul 2026
Jul 2026Kookmin University consortiumOne of 17 organisations in a KRW 22.2B KEIT advanced bio-materials programme; Daebong responsible for microbial luteinFinancial News, 28 Jul 2026
Jul 2026Business development6 NDAs at Interbiz 2026 (40+ BD meetings); 27 core follow-ups from CPHI Japan 2026MTN; CosinKorea

ESG / sustainability commitments

These are qualitative:

  • upcycled ingredients (citron seed oil, carrot leaf);

  • COSMOS organic certification;

  • vegan fermentation;

  • precision fermentation to replace crop-based extraction (lutein vs marigold).

No quantified ESG targets were found.

Cost programmes and medium-term targets

Cost programmes: none disclosed.

Medium-term financial targets: none disclosed.

Management qualitative guidance: - FY2025: improved results expected from Hydro Skin Bond, ceramides/DDS, IMDs and peptides (Feb 2025).

  • FY2026: another record expected (May 2026); H2 2026 profitability and growth expected to improve together as high-value bio materials scale (Financial News, 18 May 2026).

Third-party estimate: KIRS (8 Oct 2026) estimates FY2026 revenue of KRW 126.8B (+24.3%) and OP of KRW 13.2B (+80.1%, margin 10.4%). This is sponsored research with no rating or target price. The pharma pipeline is reflected conservatively.

Products & Services

Product-level revenue and pricing are not publicly disclosed. Launch years are given where press coverage dates them.

Cosmetic ingredients — proprietary actives ("Daebong ACTIVE")

ProductDescription / key claimsTarget customerYear surfacedSource
Hydro Skin BondBio-adhesive "skin bonding" material. Uses moisture from micro-wounds to knit skin rather than simply coating it; aimed at barrier repair. Bio-cellulose nano-fibre plus alginate-boronic acid chemistryDerma brands, post-procedure care, medical device2,023Financial News, 15 Nov 2023; Cosmorning, 30 Aug 2024
Adhesive hydrogel (all-in-one tissue adhesive)Moisture-friendly adhesion that strengthens in wet conditions; optimal at skin pH 5.5–5.8. Two patent applications filed. About 10 Korean derma companies developing products with it (2024)Derma, wound care2,024Asia Economy, 28 Aug 2024
L-PDRN FirstVegan PDRN derived from lactic-acid bacteriaAesthetic and post-procedure care2,025CosinKorea, 17 Nov 2025; 14 May 2026
DecelAge PeptidePeptide made by precision fermentation; positioned as a "longevity peptide"Anti-ageing skincare2025–26CosinKorea, 14 May 2026
RedCabbage ExoSkinExosome-type material derived from red cabbageAesthetic/derma2,025CosinKorea, 17 Nov 2025
Tremella Dual-OligoIn-house active; claims moisture signalling and pro-collagen effects beyond surface hydrationSkincare, slow-ageing2,026Medipharm Health, Jul 2026
Tremellan-MC ExtractConcentrated Tremella fuciformis polysaccharide; 48-hour incubation; about 4x mannose vs standard extract. Moisturising, anti-ageing and antioxidant (in-vitro), with in-vivo safetySkincarec.2023SCC exhibitor sheet
Korean Citron (Yuja) OilUpcycled, solvent-free oil from citron seeds discarded in citron-tea production. In-vivo anti-wrinkle, moisture and brightening claims; allergen-controlledClean/upcycled beautyc.2023SCC exhibitor sheet
Gojiberry Kombu™Postbiotic made with patented brewing technology based on Korean traditional methods; vegan fermentationMicrobiome skincarec.2023SCC exhibitor sheet
Fermented kimchi-derived Bacillus extractVegan Bacillus fermented at low temperature for 3 days; about 3x quercetin; barrier and moistureMicrobiome skincare2,023Financial News, 15 Nov 2023
Fermented Houttuynia and upcycled carrot-leaf extractsSebum control; "post-Houttuynia" positioningOil-control skincare2,023Financial News, 15 Nov 2023
Plant mucin, plant collagen, fermented yuzuVegan alternatives credited with overseas agent growth in 2024Export brands2,024Financial News, 18 Feb 2025
Protect Extract LS-2Anti-inflammatory; for seborrhoeic dermatitis and acne-prone skinAcne/derma—UL Prospector
Jeju special ingredientsFresh green tea, black ginseng water, Jeju gulfweed, Artemisia capillaris, Jeju camellia oil, daengyuji extract, basalt volcanic ash, Jeju Active Complex, ginseng-flower extractNatural/clean beautyVariousInvesting.com/S&P profile
Skin-friendly ceramides and DDS-encapsulated barrier materialsCeramide platform combined with drug-delivery (DDS) carriers for stability and penetrationBarrier repair2,025Financial News, 18 Feb 2025; CosinKorea, 17 Nov 2025

Cosmetic ingredients — distributed and partner portfolios

LineDescriptionSource
BASF materialsBase and functional materials used in "clean derma" guide formulations; BASF materials are shown at Daebong's trade boothsFinancial News, 18 Feb 2025; MTN, 13 Jul 2026
Lubrizol / Lipotec materialsPeptides and actives. Daebong credits synergy between its green-bio peptides and Lipotec products for 2024 growth. Joint "Lubrizol × Daebong LS" seminar held 29 May 2026Financial News, 18 Feb 2025; Medipharm Health 2026
Functional commoditiesAloe vera gel, beta-carotene, calamine, Diaformer, Emulgade; conditioners, emulsifiers, emollients, polymers, thickeners, preservatives, colorantsMarketScreener

Pharmaceutical raw materials and pipeline

Product / candidateDescriptionStatus (Oct 2026)Source
Respiratory APIs (incl. erdosteine)Mucolytic/expectorant and cough APIs; flagship categoryCommercial; growth credited in 2024; Japan exports after PMDA inspection (Mar 2024)Financial News, 18 Feb 2025
Hypertension APIsAntihypertensive APIs for elderly patientsCommercialFinancial News, 18 Feb 2025
Digestive and hyperlipidaemia APIsIncluding almagate (antacid)CommercialInvesting.com; MarketScreener
Other materialsBentonite, calcitriol, fish oil; excipients as agent for global suppliersCommercialMarketScreener
Pharmaceutical amino acidsFocus of the 2026 KHIDI global-GMP regulatory support programme, aimed at FDA readinessIn upgradeFinancial News, 7 Jul 2026
Liraglutide API (GLP-1 RA)32-amino-acid peptide made by a proprietary greener synthesis with shorter purification, higher purity and yield, and fewer impurities. Four patents. Scale-up at Shilpa's peptide GMP facility, with Daebong to hold domestic exclusive supplyCompany targeted Korean launch in 2026; Shilpa reported R&D-stage process complete and API process validation planned for Apr–Sep 2025. Launch not confirmed in sources reviewedMTN, 9 Sep 2024; Finance Scope, 17 Jul 2025
L-erdosteine (IMD)Single L-enantiomer, low-dose cough/expectorant; aims to lower dose burden and cost vs DL-erdosteineOut-licensing targeted by end-2026; part of 6 NDAs signed at Interbiz 2026MTN, 10 Jul 2026
Epinaconazole co-crystal (oral IMD)Oral version of the topical onychomycosis drug (the Jublia ingredient); once-daily with lower liver burden. Patents to 2040; Japan patent completed earlierOut-licensing targeted by end-2026; discussed with Japanese firms and CDMOs at CPHI Japan 2026Finance Scope, 26 Nov 2025; CosinKorea, 4 May 2026
Vonoprazan fumarate new crystal formPatent-based IMD (P-CAB acid blocker)Commercialisation being pursuedMTN, 10 Jul 2026
Azilsartan new salt and combinationPatent-based IMD (ARB antihypertensive)Commercialisation being pursuedMTN, 10 Jul 2026

Medical devices and derma products

ProductDescriptionStatusSource
DB JINO Algi Bio Cell MDClass II adhesive transparent wound dressing with 0.3% Hydro Skin Bond. Bio-responsive pH adhesion, (+)BCNF collagen-like scaffold. For post-laser/MTS, post-surgical and barrier-damage care; promotes granulation tissue and ECM synthesis. Described as Korea's first bio-cellulose composite hydrogel adhesive dressingDomestic launch planned Aug 2025 (per July 2025 report); first-MD announcement Jan 2026. Distribution enquiries from Sri Lanka, China, Japan, Bangladesh and Thailand; NDAs and pricing talks underwayCosmorning, 22 Jul 2025 & 22 Jan 2026; CosinKorea, 4 May 2026
DB JINO Multi ATO CreamDerma cream for atopic-type skin, part of the DB JINO linePresented at Interbiz 2026MTN, 10 Jul 2026

Food, feed and aquaculture

ProductDescriptionSource
Food additivesFunctional additives, proteins, amino acids, vitaminsInvesting.com
Compound fish feedSupplied to the affiliate Daebong LF Fishery Association; eel farming used to demonstrate compound-feed results versus raw feed (Korea's raw-feed share is above 70%)Financial News, 18 Apr 2022
BAS (Bio-secure Aquaculture System)Pathogen-free aquaculture system (2016 invention; patents in KR, JP, CN, EU); revenue from installation plus maintenance; 3 sites built by 2022Financial News, 18 Apr 2022
Precision-fermentation lutein (development)Microbial lutein to replace marigold extraction, for cosmetics (blue-light/photo-ageing), health foods and feedFinancial News, 7 Jul 2026

Clinical and testing services (P&K Skin Research Center)

ServiceDescriptionSource
Cosmetic human-application testsEfficacy and safety claims testing. KIRS calls P&K Korea's No. 1 skin human-application testing company. 98 in-house protocols and 473 claim phrasings developed (2024)MT, 18 Feb 2025; KIRS, Mar 2026
Health functional food testsOrders up more than 10x YoY in 2024MT, 18 Feb 2025
Beauty-device and in-vitro testingExtension areasKIRS, Mar 2026
Global regulatory consultingSupports K-beauty overseas expansionCosinKorea, 17 Nov 2025
K-Onirika Cosmetics (85.09%-owned by P&K, founded 2023)Colour-cosmetics research and contract development; projects with North American and European brandsKIRS, Mar 2026; CosinKorea, 17 Nov 2025

Financial Narrative

Sources: Butler / ETFShopping (DART-aggregated annual consolidated revenue, operating income and net income, FY2016–FY2025); Valueline (FY2025 income-statement detail, balance sheets FY2022–FY2025 and Jun-2026, cash-flow and ratio data on a trailing-twelve-month basis); MarketScreener (FY2022–FY2023 controlling net income and EPS). Units: KRW B unless stated. FY2021 balance-sheet and FY2021–FY2024 cash-flow detail were not available in the sources reviewed.

Income statement

Notes on the table:

EBITDA: The KRW 11.8B figure is computed as OP 7.33 plus depreciation 4.41 plus amortisation 0.06. Valueline's own EBITDA field shows KRW 17.6B, which appears to include non-operating items, so it is not used here.

Margins and growth

Revenue CAGR FY2021–FY2025: 5.3% (83.0 → 102.1, computed). Over ten years (FY2016 KRW 71.0B → FY2025 KRW 102.1B) the CAGR is about 4.1%. Revenue was flat for several years, from KRW 71.0B in FY2016 to 69.5B in FY2019, before the post-2020 step-up.

Longer history (context)

Source: ETFShopping; SK Securities (Jul 2020).

Commentary — income statement.

  1. A margin-compression story. Consolidated operating margin fell from 15.8% (FY2016) to 7.2% (FY2025) while revenue rose about 44%. The mix moved toward lower-margin distributed cosmetic materials. The once ~50%-margin P&K became a smaller share of profit after its FY2023 downturn.

  2. FY2023 trough. Revenue fell 6.3% and OP fell 54% to KRW 3.8B. The drivers were P&K's revenue drop (−17.3%, OP down from KRW 5.6B to 1.4B) and a weak domestic cosmetics market.

  3. FY2024 recovery. OP more than doubled to KRW 9.1B. Management credited synergies between its peptides and Lipotec products, BASF-based clean-derma formulations, strong respiratory and hypertension APIs, and Japan exports after the March 2024 PMDA inspection (Financial News, 18 Feb 2025).

  4. FY2025: record revenue, lower OP. Revenue reached KRW 102.1B (+8.6%) but OP fell 19% to KRW 7.3B. The company points to higher SG&A from the Songdo move and headcount additions, which it describes as structural investment (CosinKorea, 17 Nov 2025). Implied Q4 2025 OP was only about KRW 0.6B (FY KRW 7.3B minus 9M KRW 6.7B), on implied Q4 revenue of about KRW 24.9B.

  5. Net income above OP. FY2025 net income (KRW 11.9B) exceeded OP (KRW 7.3B). Finance income of KRW 13.7B included derivative gains of KRW 6.6B, fair-value gains on financial assets of KRW 2.9B and interest income of KRW 3.4B (Valueline TTM Dec-2025). Earnings quality is therefore heavily dependent on the investment portfolio and FX hedges.

  6. 2026 inflection risk. H1 2026 revenue rose 19.7% to KRW 62.7B, but OP fell 5.1% to KRW 5.7B and net income fell 79% to KRW 2.4B. Drivers (Dailypharm, 29 Sep 2026):

    • finance income fell from KRW 8.9B to 3.5B;

    • finance costs rose from KRW 1.6B to 6.3B, including a KRW 3.8B currency-futures loss;

    • interest expense rose about 14x to KRW 1.89B. Q2 2026 alone: revenue KRW 33.7B, OP KRW 3.7B, NI KRW 1.8B (ETFShopping). Q1 2026 basic EPS was KRW −1.16 (Investing.com).

Balance sheet

Latest interim (30 Jun 2026, Valueline):

  • total assets KRW 277.4B; cash KRW 10.5B; ST financial assets KRW 7.2B; other current assets KRW 48.4B;

  • short-term borrowings KRW 12.7B; long-term borrowings KRW 39.4B; CB KRW 28.4B; total debt about KRW 80.4B;

  • total liabilities KRW 101.3B; total equity KRW 176.2B; BPS KRW 12,787;

  • equity-method and related investments rose to KRW 16.5B from KRW 4.0B.

Commentary — balance sheet.

Asset-light to asset-heavy: Total assets grew 42% over FY2022–FY2025, funded by debt. PP&E plus investment property rose from KRW 38.4B to KRW 108.1B as the Songdo B&H Plex was built (construction contract about KRW 56.4B).

Leverage built quickly: Narrow net debt rose from KRW 12.3B (FY2022) to KRW 56.9B (FY2025) and about KRW 62.7B (Jun 2026). The KRW 30B CB (Sep 2024) and KRW 39.4B of long-term bank borrowing were the main sources.

Large financial-asset buffer: "Other current assets" of KRW 48–79B appear to be largely financial investments. Dailypharm reported fund investments of about KRW 60B in 2021 ("펀드 투자 600억"). The composition is not itemised in the sources. Including these assets, the group remains net cash on a broad basis (for example, FY2025 broad net cash of about KRW −1.8B net debt, i.e. roughly balanced).

Large minority interest: About 19% of equity belongs to minority holders, mostly the ~41–45% of P&K not owned by the group.

Low intangibles, no goodwill: No large acquisitions have been made.

Heavy working capital: Inventories rose from KRW 13.7B (FY2023) to KRW 20.3B (Jun 2026) as the distribution catalogue and export pipeline widened.

Cash flow

Source: Valueline cash-flow statement, trailing-twelve-month column at Dec-2025 (equal to FY2025).

Trailing views:

  • TTM to Jun 2026: OCF KRW 7.6B; capex KRW 9.3B; FCF about KRW −1.7B; new equity-method investment KRW 11.9B; dividends paid KRW 1.1B.

  • H1 2026 OCF fell 26.2% YoY to KRW 3.6B (Dailypharm, 29 Sep 2026).

  • FY2024 cash flows were not itemised in the sources reviewed. Construction in progress rose from KRW 9.0B to 46.4B during FY2024, which implies heavy FY2024 capex.

Commentary — cash flow. OCF of KRW 8.9B in FY2025 was well below net income of KRW 11.9B, reflecting non-cash finance gains and working-capital build. Campus capex drove deeply negative FCF of about KRW −30.6B in FY2025. Capex fell sharply in H1 2026 once the campus was finished. Free cash flow should normalise from FY2026, but there is little room for further large investment without more debt. No buybacks were made. Dividends are small (KRW 50/share; about KRW 1.0B a year).

Ratio analysis

Notes on the ratios:

  • FY2025 ROE, ROA, ROIC and interest coverage are Valueline figures.

  • FY2023 ROE, ROA for FY2023–FY2024, and the balance-sheet ratios are computed from the tables above. ROA uses consolidated net income over average assets, except FY2025, which uses Valueline's figure.

  • Working-capital days use FY2025 year-end balances against FY2025 revenue and cost of sales.

Latest trailing ratios (TTM to Jun 2026, Valueline): ROE 0.96%; ROA 0.49%; ROIC 6.83%; operating margin 6.25%; net margin 1.21%; interest coverage 2.0x; current ratio 3.64x; liabilities to owners' equity 71.4%.

Commentary — ratios.

  • Returns are low and falling: FY2025 ROE of 7.1% fell to about 1% on a trailing basis.

  • Interest coverage dropped from 14.3x (TTM Sep 2025) to 2.0x (TTM Jun 2026) as new borrowing costs arrived and operating income lagged.

  • Liquidity is ample (current ratio above 3.5x) because of the financial-asset portfolio.

  • The cash conversion cycle of about 135 days is long for a materials distributor. It reflects broad inventory carried for 800+ customers and long domestic receivable terms.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentWhat it containsKey products / services

Manufacturing (제조)

The parent company's manufacturing and trading: cosmetic ingredients (own and distributed), APIs and excipients, food/feed materials. Revenue tracks the parent's standalone revenue

Jeju actives, peptides, PDRN, exosome, Hydro Skin Bond, BASF/Lubrizol distribution; erdosteine and other respiratory/hypertension/GI APIs; feed

Research (연구)

P&K Skin Research Center and its subsidiary K-Onirika Cosmetics

Human-application efficacy and safety testing (cosmetics, health functional foods, devices), in-vitro testing, regulatory consulting; colour-cosmetics R&D (K-Onirika)

Wholesale (도매)

Small trading activity

Not detailed

Rental (임대)

New from 2025: lease income from the part of Songdo B&H Plex leased to affiliates (reclassified as investment property)

Office/R&D space leased to UCL and P&K

Revenue by Segment

Segment (KRW Bn)FY2020FY2021FY2022FY2023FY2024FY2025

Manufacturing (FY2025 = parent standalone revenue proxy)

61.265.175.272.575.879.1

Research / clinical testing (FY2025 = P&K consolidated revenue)

14.717.517.914.817.822.8

Wholesale

0.360.340.330.290.30—

Unallocated adjustments

———-0.02-0.01—

Total consolidated revenue

76.383.093.587.694.0102.1

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Results by Segment and Segment Margins & Growth (%)

MetricFY2020FY2021FY2022FY2023FY2024FY2025

Research segment / P&K operating income (KRW Bn)

7.26.55.61.42.63.9

P&K operating margin (%)

49.037.131.39.514.617.1

Parent standalone operating income (KRW Bn)

0.9—————

Parent standalone net income (KRW Bn)

———1.74.27.5

Parent standalone equity (KRW Bn)

———79.287.294.1

Revenue by Segment (%) and Segment Margins & Growth (%)

MetricFY2021FY2022FY2023FY2024FY2025

Manufacturing share of revenue (%)

78.480.482.880.677.5

Research share of revenue (%)

21.119.116.918.922.3

Manufacturing YoY growth (%)

6.415.5-3.64.64.4

Research YoY growth (%)

19.02.3-17.320.328.1

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

83.093.587.694.0102.1

Revenue growth YoY (%)

8.812.7-6.37.28.6

Cost of sales (KRW Bn)

————73.6

Gross profit (KRW Bn)

————28.5

SG&A incl. R&D (KRW Bn)

————21.2

Operating income (KRW Bn)

9.78.23.89.17.3

D&A (KRW Bn)

————4.5

EBITDA = OP + D&A (KRW Bn, computed)

————11.8

Finance income (KRW Bn)

————13.7

Finance costs (KRW Bn)

————7.1

Pre-tax income (KRW Bn)

————14.7

Income tax (KRW Bn)

————2.8

Net income, consolidated (KRW Bn)

10.011.86.29.711.9

Net income to owners of parent (KRW Bn)

—8.64.2—10.1

Non-controlling interest (KRW Bn)

————1.9

Basic EPS (KRW)

—788382—907

Diluted EPS (KRW)

—788382——

Dividend per share (KRW)

————50

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Gross margin (%)

————27.9

Operating margin (%)

11.78.84.39.77.2

EBITDA margin (%, computed)

————11.6

Net margin, consolidated (%)

12.012.67.110.311.7

R&D / revenue (%)

————5.5

Income Statement and Margin Analysis (%) (FY2016–FY2020)

MetricFY2016FY2017FY2018FY2019FY2020

Revenue (KRW Bn)

71.065.771.869.576.3

Operating income (KRW Bn)

11.29.17.97.48.1

Operating margin (%)

15.813.911.010.610.6

Balance Sheet and Per-Share Data

Metric (KRW Bn)FY2022FY2023FY2024FY2025

Total assets

186.1194.9238.7265.0

Current assets

130.2113.2115.2111.0

Cash and equivalents

7.214.218.17.6

Short-term financial assets

5.43.15.27.1

Other current assets (largely financial investments)

78.859.654.055.1

Trade receivables

23.220.719.121.5

Inventories

14.713.716.418.5

Property, plant and equipment

38.444.880.559.9

of which construction in progress

2.09.046.40.1

Investment property

0.00.00.048.2

Goodwill

0.00.00.00.0

Other intangibles

0.50.70.80.9

Investments (equity-method and other)

15.935.141.141.5

Current liabilities

34.840.940.020.4

Short-term borrowings

21.427.915.74.3

Current portion of long-term debt

2.22.10.60.7

Convertible bonds (carrying value)

0.00.025.127.2

Long-term borrowings

1.30.18.039.4

Total debt (computed, excl. leases)

24.830.249.471.6

Net debt, narrow (debt − cash − ST financial assets)

12.312.926.156.9

Total liabilities

37.741.774.790.0

Equity attributable to owners

117.2120.7131.8141.2

Non-controlling interests

31.332.532.233.7

Total equity

148.4153.2164.0174.9

Working capital (CA − CL)

95.472.375.290.6

Book value per share (KRW)

10,56710,88911,88512,737

Cash Flow

Metric (KRW Bn)FY2025

Operating cash flow

8.9

Capital expenditure (PP&E)

39.5

Intangible asset purchases

0.2

Free cash flow (OCF − capex, computed)

-30.6

Investing cash flow

-37.6

Financing cash flow

18.3

Dividends paid

1.0

Share buybacks

0.0

Depreciation and amortisation

4.5

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025

ROE, controlling basis (%)

—3.5—7.1

ROA (%)

—3.34.53.8

ROIC (%)

———6.2

Current ratio (x)

3.742.772.885.44

Total debt / total equity (%)

16.719.730.140.9

Total liabilities / owners' equity (%)

32.234.556.763.8

Net debt (narrow) / EBITDA (x)

———4.8

Interest coverage, OP / interest (x)

———4.0

Asset turnover (x)

—0.460.430.41

Days sales outstanding (days, computed)

———77

Days inventory outstanding (days, computed)

———92

Days payables outstanding (days, computed)

———34

Cash conversion cycle (days, computed)

———135

Revenue by Region and Revenue by Region (%)

Region (KRW Bn)FY2020FY2021FY2022FY2023FY2024FY2025

South Korea (domestic)

74.781.292.286.092.4100.1

Export (direct)

1.581.751.341.591.581.92

Export share of revenue (%)

2.12.11.41.81.71.9

Growth (%)

Growth (%)FY2021FY2022FY2023FY2024FY2025

Domestic YoY

8.713.5-6.77.48.3

Direct export YoY

10.8-23.418.4-0.521.5

Share Price and Market Valuation

MetricFY2022FY2023FY2024FY2025

Year-end share price (KRW)

7,9909,16013,44011,650

Year-end market cap (KRW Bn)

88.6101.6149.0129.2

Year-end P/B (x)

0.760.841.130.91

Performance Details

PerformanceReturn

YTD 2026 (vs 30 Dec 2025 close of KRW 11,650)

-37.0%

About 1 year

About -41% to -46% (Investing.com one-year change, Jul–Aug 2026)

Since end-FY2023 (about 2.8 years)

-19.9%

Since end-FY2022 (about 3.8 years)

-8.1%

5-year

Not computed (FY2021 price not available in sources)

Valuation Multiples

MultipleDaebong LSSunjin Beauty ScienceP&K (subsidiary)Hyundai BiolandSamyang KCI

P/E, trailing (x)

58.3–61.2 (TTM, depressed earnings)

17.314.7——

P/E, forward (x)

6.2 (KIRS FY2026E basis); fPER 24.6 (Butler)

10.9 (Butler fPER)

———

EV/EBITDA (x)

11.5 (TTM Jun 2026; Valueline definition)

————

EV/Sales (x)

About 1.4 (computed: market cap 81.4 + narrow net debt 62.7 + NCI 34.4 ≈ 178.5 / TTM revenue 112.4 ≈ 1.59 incl. NCI; about 1.3 excl. NCI)

————

P/B (x)

0.56–0.57

1.000.67——

P/S (x)

0.74 (TTM)

————

Analyst Ratings & Targets

DateCoverageRating / targetKey points

8 Oct 2026

KIRS (Korea IR Council, sponsored)

—

FY2026E revenue KRW 126.8B, OP KRW 13.2B; re-rating possible if cosmetics growth, co-developed materials, P&K margins and API commercialisation are confirmed

28 Sep 2026

Hana Securities

—

Report on H1 K-beauty-driven growth

Jan 2023

KIRS

—

"Three burrows" thesis (cosmetics, APIs, fish feed); valuation near historical lows

Jul 2020

SK Securities

Not Rated

Beneficiary of functional cosmetics and quality-certification demand; P&K IPO

Capital Markets

ItemDetailSource

Dividend per share, FY2025

KRW 50 (annual)

ETFShopping; Valueline

Dividend yield

About 0.43% (Valueline, on year-end basis) to about 0.66% (current price)

Valueline; ETFShopping

Payout ratio, FY2025

About 5%

ETFShopping

Dividends paid, FY2025

About KRW 1.0B

Valueline

Dividend policy

No formal policy disclosed

—

Buybacks

Treasury shares of about KRW 1.34B, held since FY2023 (about 1.25% of shares). No current buyback authorisation identified. No cancellations

Valueline; Butler

Capital Markets — Moody's / S&P / Fitch

ItemDetail

Moody's / S&P / Fitch

Not rated

Domestic ratings

None identified

Short-term borrowings

KRW 12.7B (30 Jun 2026), up from KRW 4.3B at end-FY2025

Long-term borrowings

KRW 39.4B (30 Jun 2026)

Analyst Conclusions

Management guidance

  • No numerical guidance.

  • Management expects a second consecutive record year in FY2026 (May 2026).

  • In H2 2026 it targets a higher mix of peptide and PDRN bio materials and concrete commercialisation of IMDs and generic APIs, aiming for both revenue growth and better margins (CosinKorea, 18 Aug 2026).

Third-party expectations

KIRS FY2026E: revenue KRW 126.8B (+24.3%), OP KRW 13.2B (+80.1%), OP margin 10.4%. This implies H2 2026 revenue of about KRW 64B and OP of about KRW 7.5B, versus H1 OP of KRW 5.7B. No sell-side consensus exists.

Bull case

  1. Operating leverage on a scaled base. Revenue has grown for two years and hit quarterly records (Q1 2026 KRW 29.1B; Q2 KRW 33.7B). Campus capex is largely done (H1 2026 capex well below FY2025's KRW 39.5B). Margins could revert toward the 10–12% achieved as recently as H1 2025 (11.4%), as KIRS models.

  2. Free pipeline optionality. At about 0.57x book, the market assigns little value to two IMDs targeted for out-licensing by end-2026, the liraglutide API with Shilpa and the DB JINO device line. A single licensing deal or a confirmed liraglutide supply contract would be a material re-rating trigger for a KRW 81B company.

  3. K-beauty structural growth plus P&K recovery. Korean cosmetics exports rose 27% in H1 2026. P&K's FY2025 revenue grew 27.7% with OP up 50%, and its backlog grew 20% in Q1 2026. Company-reported overseas cosmetic-material sales surged (North America +128% in H1 2026).

Bear case

  1. Earnings quality and leverage. Reported profits have relied on finance income (FY2025 KRW 13.7B vs OP KRW 7.3B). In H1 2026 that reversed: NI fell 79%, with an FX-futures loss and 14x higher interest expense. Narrow net debt is about KRW 63B and coverage is 2.0x. The headline P/E of about 60x shows how thin core earnings are.

  2. Structurally low-margin core. Operating margin has fallen for a decade, from 15.8% to 7.2%. The standalone parent historically earned 1–5% margins. Direct exports are only about 2% of revenue, and distribution dependence limits pricing power.

  3. Pipeline slippage and governance discount. Liraglutide has been guided to "next year" since 2024 with no confirmed contract. IMD deals remain at NDA stage. Related-party leasing, subsidiary loans to an impaired entity and family control may keep the stock at a persistent discount despite asset backing.

Key catalysts and monitorables (next 12 months)

TimingCatalyst / monitorable
Nov 2026Q3 2026 report: watch operating margin recovery (above 9%), FX/derivative results and interest expense
By Dec 2026Signing (or not) of L-erdosteine or epinaconazole co-crystal technology-transfer agreements
2026–27Liraglutide: Shilpa process validation → Korean import API registration → exclusive supply contract
Feb–Mar 2027FY2026 results vs KIRS (KRW 126.8B / 13.2B); dividend decision; AGM agenda
OngoingNet-debt trajectory (short-term borrowings KRW 12.7B), CB terms and any refinancing; new equity-method investment (KRW 11.9B in H1 2026) — identity and rationale
OngoingDB JINO MD distribution contracts in Asia; Azelis ASEAN traction
OngoingP&K margins and the subsidiary K-Onirika's capital position
OngoingK-beauty export data (MFDS monthly), US IOR regulation, KRW/USD rate

Analyst verdict

Daebong LS is a value stock with a profitability problem. On the surface it looks deeply cheap: it trades at about 0.57x book (BPS KRW 12,787 versus a price of about KRW 7,340), has a long operating record, holds a sizeable financial-asset portfolio and owns a majority stake in Korea's leading skin-efficacy testing house.

Two years of record revenue confirm the company is a real beneficiary of the K-beauty export cycle. Its breadth (1,200+ materials, 800+ customers, BASF and Lubrizol partnerships) gives it a defensible distribution moat in the Korean market.

The investment case, however, cannot rest on the top line. Core operating profitability has eroded for a decade, and FY2025's KRW 11.9B net income flattered a KRW 7.3B operating result. The KRW 13.7B of finance income behind that gap reversed sharply in H1 2026. Meanwhile the Songdo campus turned a net-cash balance sheet into one with about KRW 63B of narrow net debt and only 2x interest coverage. Some of that campus is leased to affiliates at an initial loss.

Until operating margins show a durable recovery toward double digits and free cash flow turns positive, the low P/B multiple is partly earned rather than purely an anomaly. KIRS's FY2026 OP estimate of KRW 13.2B implies a sharp H2 rebound.

The real upside lies in pipeline monetisation. A single IMD out-licensing deal (targeted by end-2026), a confirmed liraglutide supply contract or meaningful medical-device distribution would add high-margin revenue the market currently ignores. These events are binary, and timelines have already slipped.

Overall assessment: speculative-value, event-driven. The balance-sheet asset cover limits downside. The re-rating case depends on evidence over the next two to three quarters: margin recovery, deleveraging and at least one signed licensing deal. Investors should demand that evidence before underwriting the pipeline, and should monitor related-party dealings and the FX hedging policy closely.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameRoleTenure / backgroundAgeSource

Park Jin-oh (박진오)

CEO (대표이사); co-CEO of P&K Skin Research Center (since Mar 2021)

Second-generation owner; largest shareholder since Sep 2019; physician by training with expertise in API and cosmetic-material R&D and skin science; publicly fronting the company since at least 2009

About 55 (reported as 50 in Apr 2021)

Dailypharm, 27 Apr 2021; KIRS P&K report, Mar 2026; eToday, 2009

Park Jong-ho (박종호)

Listed alongside Park Jin-oh as company representative in corporate registries (NICE D&B / ETFShopping)

——

Incruit; ETFShopping

Son Chang-woo

Director; Head of Finance Management Department

—54

Investing.com profile

Kim Yong-kil

Director; Chief of Research & Development

—61

Investing.com profile

Jung Cheol-seug

Independent outside director

—52

Investing.com profile

Lee Hae-kwang (이해광)

Co-CEO of subsidiary P&K

——

CosinKorea, 17 Nov 2025

Major Shareholders

HolderStakeDateSource

Park Jin-oh and 8 related parties

50.93%

30 Sep 2022

KIRS, Jan 2023

of which Park Jin-oh

22.6%

30 Sep 2022

KIRS, Jan 2023

Minority shareholders (10,899 holders)

40.9%

31 Dec 2025

ETFShopping (FY2025 annual report)

Treasury shares

about 1.25%

2026

Butler

Competitive Landscape

Competitors by Segment

SegmentCompetitorTypeRelative positioning vs Daebong LS

Cosmetic ingredients (Korea)

Hyundai Bioland (KOSDAQ: 052260; Hyundai Department Store Group)

Natural cosmetic and health-food materials, brand distribution (Nestlé Health Science), medical devices

Larger and more profitable; brokers describe it as No. 1 in Korean natural cosmetic materials (Shinhan, via SmartToday)

Cosmetic ingredients (Korea)

Sunjin Beauty Science (KOSDAQ: 086710)

Cosmetic materials (UV filters, microbeads, surfactants), ODM/OEM, clinical centre (SCRC)

Similar size; also integrating materials, ODM and clinical; FDA-registered materials plant

Cosmetic and personal-care materials (Korea)

Samyang KCI (KOSDAQ: 036670; Samyang Group)

Cationic polymers, surfactants, polyglycerins, delivery systems

Larger; EcoVadis Platinum; more commodity/functional

Cosmetic actives (Korea)

BioFD&C

Plant-cell and bio actives, exosomes

Direct competitor in bio actives; also in the Kookmin consortium

Global cosmetic actives

Givaudan Active Beauty, Croda (Sederma), Symrise, DSM-Firmenich, Ashland

Global specialty-actives majors

Far larger; set the price and innovation benchmarks; Daebong competes on K-beauty speed and local service

Global (partners and competitors)

BASF, Lubrizol (Lipotec)

Global suppliers distributed by Daebong

Partners. Distribution dependence is a risk if principals go direct or switch distributors

APIs (Korea)

Domestic API makers (e.g., Kyongbo Pharm, Kukjeon Pharm, Hwail Pharm)

Generic API producers

Industry under margin pressure from drug-price reform and a high KRW/USD rate (Dailypharm headline, Sep 2026). Company-specific comparisons not compiled

Peptide APIs / GLP-1

Global peptide CDMOs and generic liraglutide API makers

—

Daebong is a new entrant through the Shilpa partnership

Clinical efficacy testing (P&K)

Global Medical Research Center, Dermapro, Sunjin's SCRC, others

Korean skin-testing CROs

KIRS/company describe P&K as the domestic No. 1

Peer Comparison FY2025

MetricDaebong LS (078140)Hyundai Bioland (052260)Sunjin Beauty Science (086710)Samyang KCI (036670)

Latest annual revenue (KRW Bn)

102.1 (FY2025)

119.5 (FY2024 consolidated); about 130.5 (FY2025 standalone)

80.8 (FY2025)

about 119.0 (FY2024E, KIRS estimate)

Revenue growth (%)

8.6 (FY2025)

17.5 (FY2024); 9M-2025 Q1–Q3 revenue growth 5–17% per quarter

1.8 (FY2025)

5.2 (FY2024E)

Operating income (KRW Bn)

7.3 (FY2025)

16.4 (FY2024); 15.2 (9M-2025)

6.1 (FY2025)

about 17.7 (FY2024E)

Operating margin (%)

7.2

13.7 (FY2024); about 14.6 (9M-2025, computed)

7.5

about 14.9 (FY2024E)

R&D intensity (%)

5.5———

Valuation (latest available)

TTM PER about 58–60x; PBR 0.56–0.57x

—

PER 17.3x; PBR 1.00x; dividend yield 2.83%

—

Company Snapshot

$71.9M

Revenue

144

Employees

1986

Founded

SWOT Analysis

Strengths

  • Scale milestone and steady top-line growth. First KRW 100B revenue year (FY2025, KRW 102.1B). Record H1 2026 revenue of KRW 62.7B (+19.7%).
  • Broad customer and product base. 1,200+ cosmetic materials and 800+ customers (KIRS, Oct 2026) reduce concentration risk. Management calls this its multi-brand, multi-category structure.
  • Global-major partnerships. BASF and Lubrizol/Lipotec distribution; joint seminars (May 2026); credited for FY2024 growth.
  • Regulated manufacturing credentials. PIC/S GMP (2015), BGMP (2022), Japan PMDA inspection passed (Mar 2024), COSMOS organic (2020).
  • Integrated clinical capability. P&K, described as domestic No. 1, delivered FY2025 revenue of KRW 22.8B (+27.7%) and OP of KRW 3.9B (17.1% margin).
  • Proprietary IP and science. Four liraglutide patents; epinaconazole IP to 2040; Chemical Engineering Journal hydrogel publication; Class II medical device launched.
  • Asset backing. BPS KRW 12,787 against a share price of about KRW 7,340 (PBR about 0.57x, Oct 2026), plus a large financial-asset portfolio.

Weaknesses

  • Low and falling operating margins. 15.8% (FY2016) → 7.2% (FY2025) → 6.25% (TTM Jun 2026).
  • Earnings depend on non-operating items. FY2025 net income (KRW 11.9B) exceeded OP (KRW 7.3B) because of KRW 13.7B finance income. The reversal in H1 2026 cut NI by 79%.
  • Negative free cash flow. FY2025 OCF KRW 8.9B against capex KRW 39.5B (FCF about KRW −30.6B).
  • Rising leverage. Narrow net debt grew from KRW 12.9B (FY2023) to about KRW 62.7B (Jun 2026). Interest coverage fell to 2.0x (TTM Jun 2026).
  • Minimal direct exports. About 1.9% of revenue (FY2025 KRW 1.92B). No overseas subsidiaries.
  • Long cash conversion cycle. About 135 days (FY2025, computed), with inventories up to KRW 20.3B (Jun 2026).

Opportunities

  • K-beauty export tailwind. Korean cosmetics exports rose 12.3% to USD 11.4B in 2025 and 27% in H1 2026.
  • IMD out-licensing. L-erdosteine and the epinaconazole co-crystal are targeted for end-2026; 6 NDAs signed (Jul 2026); 27 CPHI Japan follow-ups.
  • GLP-1 peptide APIs. Liraglutide with Shilpa; Korean exclusive supply targeted.
  • Medical-beauty devices. DB JINO MD enquiries from five Asian countries (May 2026).
  • High-value bio materials. PDRN, peptides and exosomes are planned to grow as a share of sales in H2 2026. Natural ingredients are forecast to grow at 9.0% CAGR globally.
  • Operating leverage at Songdo. Freed Namdong capacity can support own production (IB Tomato, Apr 2026). KIRS models a FY2026 OP margin of 10.4%.

Threats

  • API sector stress. Drug-price reform and a high exchange rate are pressuring Korean API makers (Dailypharm, Sep 2026).
  • FX and derivative losses. KRW 3.8B currency-futures loss in H1 2026.
  • Pipeline timing risk. The liraglutide launch has been guided to 2026 since Sep 2024 and is still unconfirmed. KIRS treats the pharma pipeline conservatively.
  • Distribution-principal risk. Distributed BASF and Lubrizol materials could be re-channelled.
  • Subsidiary drag. P&K's capital-impaired subsidiary (loans of about KRW 1.4B, Sep 2026).
  • US import-regulation changes (IOR) that could slow K-beauty SME exports, Daebong's indirect customer base.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
13 May 2025Shares rise about 4.8% to KRW 14,300 on hopes of Korean exclusive supply of Shilpa liraglutide Asia EconomyShows GLP-1 optionality priced into the stock near its peak
15 May 2025Q1 2025 quarterly report filed ETFShopping filing listRoutine
2–4 Jul 2025in-cosmetics Korea 2025 exhibition NewswireIngredient marketing
17 Jul 2025Shilpa reports liraglutide R&D process complete; API process validation planned Apr–Sep 2025. Daebong says mass production is possible from year-end, when the originator patent expires Finance ScopeSupports 2026 launch timeline (not yet confirmed)
22 Jul 2025Interbiz 2025: 8 strategic technologies; about 50 company meetings; DB JINO MD domestic launch planned the following month CosmorningPipeline marketing
14 Aug 2025H1 2025 report: revenue KRW 52.4B; OP KRW 6.0B; NI KRW 11.5B Dailypharm, 29 Sep 2026Strong H1 2025 base (OP margin 11.4%)
14 Nov 2025Q3 2025: 9M revenue KRW 77.2B (+9.1%); OP KRW 6.7B; exports +6%; SG&A up on Songdo move CosinKoreaMargin pressure begins
14 Nov 2025P&K 9M revenue KRW 17.0B (+34%), OP KRW 3.2B (+73%) CosinKoreaSubsidiary recovery
21 Nov 2025IMD and obesity-drug conference at Paradise City, Incheon: 138 people from 77 pharma companies; Shilpa CTO presents a Korea and Thailand GLP-1 roadmap Finance Scope, 26 Nov 2025Repositioning toward drug development
18 Dec 2025Songdo B&H Plex grand opening MT, 19 Dec 2025New fixed-cost base; integration story
9 Jan 2026MFDS: Korea's 2025 cosmetics exports reach a record USD 11.4B NewsisEnd-market tailwind
22 Jan 2026First in-house medical device: DB JINO Algi Bio Cell MD CosmorningMedical-beauty entry
27 Feb 2026FY2025 results: revenue KRW 102.1B (first above KRW 100B); OP KRW 7.3B (−19%) Finance Scope; ButlerScale milestone; profit decline
23 Mar 2026FY2025 annual report filed ETFShopping; IB TomatoHead-office change to Songdo disclosed
31 Mar 2026AGM results filed ButlerGovernance
10 Apr 2026IB Tomato: about half of the Songdo R&D centre reclassified to investment property; rental loss-making in year 1Capital-allocation scrutiny
4 May 2026CPHI Japan 2026: 27 core follow-ups; NDA and licensing talks on IMDs and the MD cream CosinKoreaLicensing pipeline
14 May 2026Azelis Indonesia partnership publicised; L-PDRN, DecelAge and ExoSkin attract interest CosinKoreaASEAN
15–18 May 2026Q1 2026: record quarterly revenue KRW 29.1B; overseas +37%; profit down on oil prices, FX, interest and D&A. P&K Q1 revenue KRW 6.2B, OP KRW 1.0B; backlog KRW 6.0B (+20%) Financial News, 18 May 2026Growth/profit divergence
29 May 2026Lubrizol × Daebong LS beauty-ingredient seminar Medipharm HealthPartner depth
Jun–Jul 2026Selected for KHIDI 2026 global GMP regulatory support programme CosinKorea; Financial NewsFDA/EU capability
1–3 Jul 2026in-cosmetics Korea 2026: about 800 consultations; pre-show technical seminar at B&H Plex for overseas agents Medipharm Health; MTNCommercial traction
6–7 Jul 2026Voluntary disclosure: lead organisation of KEIT microbial lutein project (KRW 5B, to Dec 2030) Butler; Financial NewsNon-dilutive R&D funding
10 Jul 2026Interbiz 2026: 6 NDAs; L-erdosteine and epinaconazole co-crystal out-licensing targeted end-2026 MTN; GeconomyCatalyst setup
28 Jul 2026Named in the Kookmin University-led KRW 22.2B advanced bio-materials programme Financial NewsR&D network
14 Aug 2026H1 2026 report: revenue KRW 62.7B (+19.7%); OP KRW 5.7B (−5.1%); exports +52% CosinKorea, 18 Aug 2026Record sales, lower OP
21 Sep 2026Investor-relations meeting (IR) held Butler disclosure listInvestor outreach
23 Sep 2026Dailypharm: P&K's loans to its capital-impaired subsidiary approach KRW 1.4BRelated-party / subsidiary risk
28 Sep 2026Hana Securities report (no rating); headline cites H1 sales growth of 28%. This differs from the company's 19.7%, possibly a segment basis StockHubCoverage
29 Sep 2026Dailypharm: H1 NI −79%; finance costs 3.9x; ST borrowings 3x; OCF −26%Balance-sheet and earnings-quality concern
8 Oct 2026KIRS report: FY2026E revenue KRW 126.8B, OP KRW 13.2B; PER 6.2x and PBR 0.6x on its estimates, at the bottom of the 5-year band Dailypharm; NewsisValuation-gap thesis
14 Oct 2026Recruiting for cosmetic-materials technical sales (2026 new hires) SuperookieContinued commercial build-out
19 Oct 2026Share price closes at KRW 7,340 (market cap about KRW 81.4B) ValuelineNear the 52-week low of KRW 6,780

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

6 charts
Income Statement: Revenue & Gross Profit: Revenue rose from KRW 83 Bn in FY2021 to KRW 102.1 Bn in FY2025.
Daebongls.Co., Ltd. — Income Statement: Revenue & Gross Profit
Series (KRW Bn)FY2021FY2022FY2023FY2024FY2025
Revenue8393.587.694102.1
Cost of sales————73.6
Gross profit————28.5

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Valueline / DataHero — Daebong LS balance sheet, income statement, cash flow, investment metrics (data to 26.2Q; price 19 Oct 2026)
  2. Butler — annual results FY2021–FY2025, disclosure list
  3. ETFShopping — 10-year results, filings, ownership, dividend
  4. MarketScreener — segment and geographic breakdown FY2020–FY2024
  5. Investing.com — company profile, executives, price data
  6. Incruit (NICE D&B) — standalone financials, employees, incorporation date
  7. KIRS report via Dailypharm, 8 Oct 2026
  8. Dailypharm, H1 2026 earnings analysis, 29 Sep 2026
  9. CosinKorea, H1 2026 record sales, 18 Aug 2026
  10. CosinKorea, 9M 2025 results, 17 Nov 2025
  11. Financial News, FY2024 results, 18 Feb 2025
  12. Financial News, Q1 2026 results, 18 May 2026
  13. Financial News, lutein national project, 7 Jul 2026
  14. IB Tomato, Songdo R&D centre reclassification, 10 Apr 2026
  15. MT, Songdo B&H Plex grand opening, 19 Dec 2025
  16. Dealsite, Songdo construction contract, 1 Apr 2024
  17. Finance Scope, Shilpa GLP-1 progress, 17 Jul 2025
  18. Finance Scope, IMD conference, 26 Nov 2025
  19. Dailypharm, Shilpa liraglutide CDMO, 11 Mar 2025
  20. MTN, Interbiz 2026 NDAs, 10 Jul 2026
  21. CosinKorea, CPHI Japan 2026, 4 May 2026
  22. Cosmorning, first medical device, 22 Jan 2026
  23. Asia Economy, adhesive hydrogel / Flen Health, 28 Aug 2024
  24. Edaily (via Daum), KRW 30B CB without refixing, 8 Oct 2024
  25. Dailypharm, parent vs consolidated margins and ownership, 27 Apr 2021
  26. KIRS company report (Jan 2023)
  27. SK Securities report (Jul 2020)
  28. MT, P&K FY2024 results, 18 Feb 2025
  29. ETFShopping, P&K financials
  30. SmartToday, Hyundai Bioland FY2024
  31. Butler, Sunjin Beauty Science
  32. MFDS 2025 cosmetics exports via Newsis, 9 Jan 2026
  33. MFDS 2025 production/export statistics via Cosmorning
  34. Persistence Market Research, cosmetic ingredients market
  35. Global Market Insights, cosmetic actives market
  36. SCC exhibitor sheet (Daebong LS products)
  37. Financial News, BAS aquaculture / feed, 18 Apr 2022

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.